Cadrenal Therapeutics, Inc. Quarterly Share-based Payment Arrangement, Expense in USD from Q1 2023 to Q2 2025

Taxonomy & unit
us-gaap: USD
Description
Amount of expense for award under share-based payment arrangement. Excludes amount capitalized.
Summary
Cadrenal Therapeutics, Inc. quarterly/annual Share-based Payment Arrangement, Expense history and growth rate from Q1 2023 to Q2 2025.
  • Cadrenal Therapeutics, Inc. Share-based Payment Arrangement, Expense for the quarter ending June 30, 2025 was $593K, a 207% increase year-over-year.
  • Cadrenal Therapeutics, Inc. Share-based Payment Arrangement, Expense for the twelve months ending June 30, 2025 was $2.2M, a 260% increase year-over-year.
  • Cadrenal Therapeutics, Inc. annual Share-based Payment Arrangement, Expense for 2024 was $1.42M, a 99.8% increase from 2023.
  • Cadrenal Therapeutics, Inc. annual Share-based Payment Arrangement, Expense for 2023 was $710K, a 23.5% decline from 2022.
Share-based Payment Arrangement, Expense, Trailing 12 Months (USD)
Share-based Payment Arrangement, Expense, Quarterly (USD)
Share-based Payment Arrangement, Expense, YoY Quarterly Growth (%)
Period TTM Value Value YoY Chg Change % Start Date End Date Report Filed
Q2 2025 $2.2M $593K +$400K +207% Apr 1, 2025 Jun 30, 2025 10-Q 2025-08-11
Q1 2025 $1.81M $549K +$386K +237% Jan 1, 2025 Mar 31, 2025 10-Q 2025-05-08
Q4 2024 $1.42M $763K +$660K +640% Oct 1, 2024 Dec 31, 2024 10-K 2025-03-13
Q3 2024 $759K $300K +$147K +96% Jul 1, 2024 Sep 30, 2024 10-Q 2024-11-07
Q2 2024 $612K $193K +$25.3K +15.1% Apr 1, 2024 Jun 30, 2024 10-Q 2025-08-11
Q1 2024 $587K $163K -$124K -43.2% Jan 1, 2024 Mar 31, 2024 10-Q 2025-05-08
Q4 2023 $710K $103K Oct 1, 2023 Dec 31, 2023 10-K 2025-03-13
Q3 2023 $153K Jul 1, 2023 Sep 30, 2023 10-Q 2024-11-07
Q2 2023 $168K Apr 1, 2023 Jun 30, 2023 10-Q 2024-08-07
Q1 2023 $286K Jan 1, 2023 Mar 31, 2023 10-Q 2024-05-09
* An asterisk sign (*) next to the value indicates that the value is likely invalid.